Business
West Pharmaceutical Services makes injectable-drug packaging and delivery components.
West Pharmaceutical Services returned to growth with a 19% margin and strong free cash flow, though inventory and stock compensation rose faster than sales.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 6.3%OK
- Profitability — Net income grew 0.2% to $493.7M from $492.7MOK
- Cash flow — Free cash flow grew 69.6% to $468.9M from $276.4MOK
- Margins — Operating margin contracted 67 bps to 19.03%Watch
- Accounting — High-quality drug-packaging recoveryNote
- Insiders — 0 purchases and 2 salesNote
Where the revenue comes from
Fiscal 2025, as WEST PHARMACEUTICAL SERVICES INC reports it. History and quarterly detail are in the app.
- Proprietary Products$2.5B
- Contract-Manufactured Products$582.0M
Leadership changes
From WEST PHARMACEUTICAL SERVICES INC's own filings, the day they're filed.
- Shane Campbell · President · appointmenteff. 2025-05-05
- Cindy Reiss-Clark · Chief Commercial Officer · departureeff. 2025-03-07
- Cindy Reiss-Clark · Chief Commercial Officer · departureeff. 2025-03-07
Latest filings
- 8-K · Company announcement2026-06-01
- 8-K · Company announcement2026-05-11
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-04-23
- 10-Q · Quarterly report2026-04-23
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about WEST PHARMACEUTICAL SERVICES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.